title: Pharmacological treatment of child and adolescent disruptive behaviour disorders: between the scylla and charybdis, what do the data say?
authors.affiliation: President, Canadian Academy of Child and Adolescent Psychiatry, Ottawa, Ontario; Associate Professor, University of Calgary, Calgary, Alberta; Division Head, Child and Adolescent Mental Health and Addictions, Calgary, Alberta; Outpatient Section Chief, Child and Adolescent Psychiatry, Calgary, Alberta; Consulting Psychiatrist, Young Adult Outpatient Services, Calgary, Alberta; Alberta Health Services and University of Calgary, Calgary, Alberta.
authors.forename: Thomas C R
authors.initials: TC
authors.lastname: Wilkes
authors.affiliation: Chair of the Professional Standards Committee, Canadian Academy of Child and Adolescent Psychiatry, Ottawa, Ontario; Child and Adolescent Psychiatrist, Early Psychosis Intervention Service, Queen Alexandra Centre for Children's Health, Island Health, Victoria, British Columbia; Clinical Associate Professor, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia; Affiliate Associate Professor, Division of Medical Sciences, University of Victoria, Victoria, British Columbia.
authors.forename: Mary Kay
authors.initials: MK
authors.lastname: Nixon
mesh_terms: D000293:Adolescent; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D002648:Child; D006801:Humans